AimwellBio Opens Intelligence Map Publicly
Analysis based on 6 articles · First reported Sep 02, 2026 · Last updated Sep 02, 2026
This event is a minor corporate announcement from a small OTC-listed company, likely to have negligible impact on broad financial markets. It may generate modest interest among micro-cap investors and stakeholders in the healthcare intelligence niche.
Aimwell Partners, the parent company of Aimwell Bio, announced on September 2, 2026 that it has made its global biopharma intelligence map, AIMN:ATLAS, publicly viewable without login at aimwellbio.com/atlas. The map displays thousands of companies and entities, eleven regulatory agency zones with scores, and a curated signal corpus of over 9,200 indexed signals from sources including PubMed, the U.S. FDA, United States — ClinicalTrials.gov, and SEC EDGAR. Notably, the highest-scored regulatory zone is Saudi Arabia's SFDA. The company also confirmed that Dr. Chris A. Jones, who joined the Board of Advisors following the Trustr acquisition on August 17, has initiated introductions with multiple companies and is in active discussions with physicians and scientists for advisory roles. CEO Dan Morgan emphasized the company's transparency and the open-door policy for collaboration inquiries.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard